Todd Kinsella
Corporate Officer/Principal chez Vividion Therapeutics, Inc.
Postes actifs de Todd Kinsella
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2017 | - |
Historique de carrière de Todd Kinsella
Anciens postes connus de Todd Kinsella
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Todd Kinsella
| University of Arizona | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Bourse
- Insiders
- Todd Kinsella
- Expérience
